AI-Discovered Drug Reverses Aging Markers in Study, Biotech Says

Insilico Medicine reported that its AI-discovered drug for idiopathic pulmonary fibrosis also reduced biological markers of aging in preclinical studies. These findings suggest that treatments developed for specific conditions may have broader applications in addressing age-related cellular decline. The results highlight the potential for AI-driven drug discovery to identify therapeutic secondary uses for existing compounds.